MDCX
Price
$1.64Alerts
Change
-$0.19 (-10.38%)
Updated
Nov 11 closing price
Capitalization
134.1M
Intraday BUY SELL Signals
SNY
Price
$48.43Alerts
Change
+$0.20 (+0.41%)
Updated
Nov 11 closing price
Capitalization
112.71B
79 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MDCX vs SNY

MDCX vs SNY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MDCX vs. SNY commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDCX is a Hold and SNY is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MDCX with price predictions
Nov 10, 2026

MDCX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for MDCX turned positive on October 27, 2026. Looking at past instances where MDCX's MACD turned positive, the stock continued to rise in 19 of 23 cases over the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +7.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDCX advanced for three days, in 70 of 85 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

MDCX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDCX as a result. In 40 of 45 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDCX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for MDCX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MDCX's P/B Ratio (-76.034) is very low in comparison to the industry average of (-1.421). P/E Ratio (-0.792) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. MDCX's P/S Ratio (0.000) is slightly lower than the industry average of (4.033).

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. MDCX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.

A.I.Advisor
a Summary for SNY with price predictions
Nov 10, 2026

SNY in upward trend: price rose above 50-day moving average on October 29, 2026

SNY moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on SNY as a result. In 55 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.

The Moving Average Convergence Divergence (MACD) for SNY just turned positive on October 15, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in 22 of 46 cases over the following month. The odds of a continued upward trend are 48%.

The 10-day moving average for SNY crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.

Following a +2.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 154 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.

The Aroon Indicator entered an Uptrend today. In 160 of 284 cases where SNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

SNY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating fairly steady price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock slightly worse than average.

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.629) is normal, around the industry mean (-1.421). P/E Ratio (28.596) is within average values for comparable stocks, (21.700). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY's Dividend Yield (0.169) is considerably higher than the industry average of (0.038). P/S Ratio (1.829) is also within normal values, averaging (4.033).

FUNDAMENTALS RATINGS
SNY: Fundamental Ratings
SNY
OUTLOOK RATING
1..100
45
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
PROFIT vs RISK RATING
1..100
63
SMR RATING
1..100
81
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
7
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MDCXSNY
RSI
ODDS (%)
Bullish Trend 3 days ago
67%
Bearish Trend 2 days ago
41%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
53%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 2 days ago
56%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
48%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
53%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
49%
Advances
ODDS (%)
Bullish Trend 9 days ago
82%
Bullish Trend 2 days ago
51%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend about 1 month ago
52%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 2 days ago
47%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
56%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (MDCX: $1.83 vs. SNY: $48.23)
Brand notoriety: MDCX and SNY are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: MDCX: 63% vs. SNY: 118%
Market capitalization -- MDCX: $134.1M vs. SNY: $112.71B
MDCX [@Pharmaceuticals: Major] is valued at $134.1M. SNY’s [@Pharmaceuticals: Major] market capitalization is $112.71B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.21T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $215.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDCX’s FA Score shows that 2 FA rating(s) are green while SNY’s FA Score has 1 green FA rating(s).

  • MDCX’s FA Score: 2 green, 3 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, SNY is a better buy in the long-term than MDCX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDCX’s TA Score shows that 5 TA indicator(s) are bullish while SNY’s TA Score has 6 bullish TA indicator(s).

  • MDCX’s TA Score: 5 bullish, 3 bearish.
  • SNY’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SNY is a better buy in the short-term than MDCX.

Price Growth

MDCX (@Pharmaceuticals: Major) experienced а -9.85% price change this week, while SNY (@Pharmaceuticals: Major) price change was +6.40% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.33%. For the same industry, the average monthly price growth was +2.53%, and the average quarterly price growth was +7.15%.

Reported Earning Dates

SNY is expected to report earnings on Jan 29, 2027.

Industries' Descriptions

@Pharmaceuticals: Major (-1.33% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
Interact to see
Advertisement

MDCX and

Correlation & Price change

A.I.dvisor tells us that MDCX and BMY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDCX and BMY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDCX
1D Price
Change %
MDCX100%
N/A
BMY - MDCX
29%
Poorly correlated
+1.06%
SNY - MDCX
21%
Poorly correlated
+0.23%
MRK - MDCX
15%
Poorly correlated
-0.48%
NVS - MDCX
14%
Poorly correlated
-0.26%
AMGN - MDCX
13%
Poorly correlated
N/A
More

SNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNY has been loosely correlated with PFE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNY
1D Price
Change %
SNY100%
+0.23%
PFE - SNY
47%
Loosely correlated
+0.44%
JNJ - SNY
36%
Loosely correlated
-0.47%
MRK - SNY
35%
Loosely correlated
-0.48%
AMGN - SNY
35%
Loosely correlated
N/A
GILD - SNY
34%
Loosely correlated
+0.92%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TSLG4.930.05
+1.02%
Leverage Shares 2X Long TSLA Daily ETF (TSLG)
VYLD30.67-0.12
-0.40%
Inverse Vix Short-Term Futures Etns Due March 22, 2045
CRUX29.02-0.15
-0.51%
Columbia Core Bond ETF (CRUX)
BSCZ19.61-0.13
-0.68%
Invesco BulletShares 2035 Corporate Bond ETF (BSCZ)
ANV23.59-0.50
-2.07%
GraniteShares Autocallable NVDA ETF (ANV)